- Home
- ELEV
as 05-14-2025 4:00pm EST
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 20.0M | IPO Year: | 2021 |
| Target Price: | $2.94 | AVG Volume (30 days): | 975.2K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $4.33 | Next Earning Date: | 05-23-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevation Oncology Inc. Common stock News
ELEV Breaking Stock News: Dive into ELEV Ticker-Specific Updates for Smart Investing
Zacks
15 hours ago
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
PR Newswire
19 days ago
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
BioPharma Dive
a month ago
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech
PR Newswire
2 months ago
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
MT Newswires
2 months ago
Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5
Zacks
2 months ago
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Investing.com
2 months ago
Elevation Oncology downgraded as it halts lead asset on disappointing trials
MT Newswires
2 months ago
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10
Compare ELEV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELEV Elevation Oncology Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.